ArticleNature communications2017
Dendrogenin A drives LXR to trigger lethal autophagy in cancers.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Role of the autophagy-related marker LC3 expression in hepatocellular carcinoma: a meta-analysis.Journal of cancer research and clinical oncology · 2020Pooled it
- PAX9 activates autophagy through a transcription-dependent mechanism, promoting EGFR degradation to restrict cell survival in oral cancer.British journal of cancer · 2026Article
- Cholesterol Reprogramming in Acute Myeloid Leukemia: Integrating Tumor-Intrinsic Metabolism and Immune Crosstalk.Diseases (Basel, Switzerland) · 2026Review
- Dairy Processing and Breast Cancer: A Hypothesis-Generating Framework Linking Bioactive Lipid Derivatives to Epidemiological Heterogeneity.Advances in nutrition (Bethesda, Md.) · 2026Review
- NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- The Phospholipid Bis(monoacylglycero)Phosphate Confers Antitumour Immunogenicity to Exosomes Secreted by Dendrogenin A, Which Activates Its Biosynthesis in Tumour Cells.Journal of extracellular vesicles · 2026Article
- The Role of Cholesterol Metabolism and Its Regulation in Tumor Development.Cancer medicine · 2025Review
- Role of Protein Regulators of Cholesterol Homeostasis in Immune Modulation and Cancer Pathophysiology.Endocrinology · 2025Review
- Current Understanding of the Role of Autophagy in the Treatment of Myeloid Leukemia.International journal of molecular sciences · 2024Review
- Review
- Exploring the nexus of nuclear receptors in hematological malignancies.Cellular and molecular life sciences : CMLS · 2024Review
- Liver X Receptors (LXRs) in cancer-an Eagle's view on molecular insights and therapeutic opportunities.Frontiers in cell and developmental biology · 2024Review
- Meta‑analysis of the autophagy‑associated protein LC3 as a prognostic marker in colorectal cancer.Experimental and therapeutic medicine · 2023Article
- Review
- Serine hydroxymethyltransferase 2 knockdown induces apoptosis in ccRCC by causing lysosomal membrane permeabilization via metabolic reprogramming.Cell death & disease · 2023Article
- The Liver X Receptor Is Selectively Modulated to Differentially Alter Female Mammary Metastasis-associated Myeloid Cells.Endocrinology · 2022Article
- Structural enzymology of cholesterol biosynthesis and storage.Current opinion in structural biology · 2022Review
- The dual role of autophagy in acute myeloid leukemia.Journal of hematology & oncology · 2022Review
- Article
- Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome-enriched vesicles.Journal of extracellular vesicles · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 5 institutions in 2 countries.
Gregory SegalaUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Marion DavidUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Philippe de MedinaAFFICHEM, Toulouse, F-31400, France.
Mathias C PoirotUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Nizar SerhanUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
François VergezService d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, F-31100, France.
Aurelie MougelUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Estelle SalandUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Chemoresistance, Stem Cells and Metabolism in Acute Myeloid Leukemia, Toulouse, F-31037, France.
Kevin CarayonUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Julie LeignadierUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Nicolas CaronAFFICHEM, Toulouse, F-31400, France.
Maud VoisinUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Julia CherierUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Laetitia LigatUMR 1037-CRCT, Pole Technologique, Toulouse, F-31037, France.
Frederic LopezUMR 1037-CRCT, Pole Technologique, Toulouse, F-31037, France.
Emmanuel NoguerAFFICHEM, Toulouse, F-31400, France.
Arnaud RivesAFFICHEM, Toulouse, F-31400, France.
Bruno PayréCentre de Microscopie Electronique Appliquée à la Biologie, Toulouse, F-31062, France.
Talal Al SaatiINSERM-US006 ANEXPLO/CREFRE F-31024, Toulouse, F-31024, France.
Antonin LamaziereLaboratory of Mass Spectrometry, INSERM ERL 1157, CNRS UMR 7203 LBM, Sorbonne Universités-UPMC, CHU Saint-Antoine, Paris, F-75012, France.
Gaëtan DespresLaboratory of Mass Spectrometry, INSERM ERL 1157, CNRS UMR 7203 LBM, Sorbonne Universités-UPMC, CHU Saint-Antoine, Paris, F-75012, France.
Jean-Marc LobaccaroUniversité de Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, F-63001, France.ORCID http://orcid.org/0000-0001-9890-2392
Silvere BaronUniversité de Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, F-63001, France.
Cecile DemurService d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, F-31100, France.
Fabienne de ToniUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Chemoresistance, Stem Cells and Metabolism in Acute Myeloid Leukemia, Toulouse, F-31037, France.
Clément LarrueUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Chemoresistance, Stem Cells and Metabolism in Acute Myeloid Leukemia, Toulouse, F-31037, France.
Helena BoutzenUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Chemoresistance, Stem Cells and Metabolism in Acute Myeloid Leukemia, Toulouse, F-31037, France.
Fabienne ThomasUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Dose Individualisation of Anticancer Drugs Team, Toulouse, F-31037, France.
Jean-Emmanuel SarryUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Chemoresistance, Stem Cells and Metabolism in Acute Myeloid Leukemia, Toulouse, F-31037, France.
Marie TosoliniUMR 1037-CRCT, Pole Technologique, Toulouse, F-31037, France.ORCID http://orcid.org/0000-0001-5278-5952
Didier PicardDépartement de Biologie Cellulaire, Université de Genève, Genève, 1211, Switzerland.
Michel RecordUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France.
Christian RécherUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Chemoresistance, Stem Cells and Metabolism in Acute Myeloid Leukemia, Toulouse, F-31037, France. recher.christian@iuct-oncopole.fr.
Marc PoirotUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France. marc.poirot@inserm.fr.ORCID http://orcid.org/0000-0002-5711-6624
Sandrine Silvente-PoirotUMR 1037-CRCT, Université de Toulouse, INSERM, UPS, Cholesterol Metabolism and Therapeutic Innovations Team, Toulouse, F-31037, France. sandrine.poirot@inserm.fr.
Université Toulouse III - Paul Sabatier · FRCentre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Toulouse · FRUniversity of Geneva · CHInserm · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendrogenin A (DDA) is a newly discovered cholesterol metabolite with tumor suppressor properties. Here, we explored its efficacy and mechanism of cell death in melanoma and acute myeloid leukemia (AML). We found that DDA induced lethal autophagy in vitro and in vivo, including primary AML patient samples, independently of melanoma Braf status or AML molecular and cytogenetic classifications. DDA is a partial agonist on liver-X-receptor (LXR) increasing Nur77, Nor1, and LC3 expression leading to autolysosome formation. Moreover, DDA inhibited the cholesterol biosynthesizing enzyme 3β-hydroxysterol-Δ
Indexed as
Leukemia, Myeloid, AcuteMelanomaAnimalsAntineoplastic AgentsAutophagyCell DeathCell Line, TumorCholestanolsDrug Partial AgonismGene ExpressionHEK293 CellsHL-60 CellsHumansImidazolesIn Vitro TechniquesLiver X Receptors5-hydroxy-6-(2-(1H-imidazol-4-yl)ethylamino)cholestan-3-olAntineoplastic AgentsCholestanolsImidazolesLiver X ReceptorsMAP1LC3A protein, humanMembrane Transport ProteinsMicrotubule-Associated ProteinsNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1OSCP1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.